Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 14, 2009 - Issue 3
Submit an article Journal homepage
472
Views
37
CrossRef citations to date
0
Altmetric
Reviews

Emerging drugs for insomnia: new frontiers for old and novel targets

Shannon S Sullivan Stanford University Sleep Medicine Center, 450 Broadway Street, MC 5704, Redwood City, CA 94063, USA +1 650 723 6601; +1 650 721 3465; [email protected]
, MD &
Christian Guilleminault Stanford University Sleep Medicine Center, 450 Broadway Street, MC 5704, Redwood City, CA 94063, USA +1 650 723 6601; +1 650 721 3465; [email protected]
, MD DBiol
Pages 411-422 | Published online: 27 Aug 2009

Citations (37)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Roberto Mandrioli & Laura Mercolini. (2015) Discontinued anxiolytic drugs (2009 – 2014). Expert Opinion on Investigational Drugs 24:4, pages 557-573.
Read now
Shannon Sullivan. (2012) Update on emerging drugs for insomnia. Expert Opinion on Emerging Drugs 17:3, pages 295-298.
Read now
T. Roth, R.K. Bogan, L. Culpepper, K. Doghramji, P. Doghramji, C. Drake, J.H. Grauke, P. Knoepflmacher, M. Sateia, D. Silvershein & M.J. Thorpy. (2010) Excessive sleepiness: under-recognized and essential marker for sleep/wake disorder management. Current Medical Research and Opinion 26:sup2, pages S3-S27.
Read now

Articles from other publishers (34)

Bernice M. Wulterkens, Lieke W. A. Hermans, Pedro Fonseca, Jerryll Asin, Nanny Duis, Hennie C. J. P. Janssen, Sebastiaan Overeem & Merel M. van Gilst. (2023) Sleep structure in patients with COMISA compared to OSA and insomnia. Journal of Clinical Sleep Medicine 19:6, pages 1051-1059.
Crossref
Denis I. Burchakov. (2023) Sleep disturbances in pregnancy: features of diagnosis and therapy: A review. Gynecology 24:6, pages 471-477.
Crossref
Laura P. McLafferty, Meredith Spada & Priya Gopalan. (2022) Pharmacologic Treatment of Sleep Disorders in Pregnancy. Sleep Medicine Clinics 17:3, pages 445-452.
Crossref
Jingjing Qian, Lin Zheng, Guowan Su, Mingtao Huang, Donghui Luo & Mouming Zhao. (2021) Identification and Screening of Potential Bioactive Peptides with Sleep-Enhancing Effects in Bovine Milk Casein Hydrolysate. Journal of Agricultural and Food Chemistry 69:38, pages 11246-11258.
Crossref
Jasper Dingemanse, Pascal Charef, Jed Black & Chris Gouws. (2021) Investigation of the effect of the dual orexin receptor antagonist almorexant on ophthalmological, spermatogenic, and hormonal variables in healthy male subjects. Biomedicine & Pharmacotherapy 133, pages 110955.
Crossref
Benjamin Berger, Sander Brooks, Rob Zuiker, Muriel Richard, Clemens Muehlan & Jasper Dingemanse. (2020) Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects. CNS Drugs 34:12, pages 1253-1266.
Crossref
Laura P. McLafferty, Meredith Spada & Priya Gopalan. (2018) Pharmacologic Treatment of Sleep Disorders in Pregnancy. Sleep Medicine Clinics 13:2, pages 243-250.
Crossref
Bibia Heidmann, John Gatfield, Catherine Roch, Alexander Treiber, Simone Tortoioli, Christine Brotschi, Jodi T. Williams, Martin H. Bolli, Stefan Abele, Thierry Sifferlen, François Jenck & Christoph Boss. (2016) Discovery of Highly Potent Dual Orexin Receptor Antagonists via a Scaffold-Hopping Approach. ChemMedChem 11:19, pages 2132-2146.
Crossref
Yinfeng Yang, Yan Li, Yanqiu Pan, Jinghui Wang, Feng Lin, Chao Wang, Shuwei Zhang & Ling Yang. (2016) Computational Analysis of Structure-Based Interactions for Novel H1-Antihistamines. International Journal of Molecular Sciences 17:1, pages 129.
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs 65 76 .
Nadia M. Ahmad. 2015. Innovative Drug Synthesis. Innovative Drug Synthesis 223 242 .
Yaxin Zheng, Jiming Wu, Xuesong Feng, Ying Jia, Jian Huang, Zhihui Hao, Songyan Zhao & Jinhui Wang. (2015) In silico Analysis and Experimental Validation of Lignan Extracts from Kadsura longipedunculata for Potential 5-HT1AR Agonists. PLOS ONE 10:6, pages e0130055.
Crossref
Yu Yoshida, Yoshimitsu Naoe, Taro Terauchi, Fumihiro Ozaki, Takashi Doko, Ayumi Takemura, Toshiaki Tanaka, Keiichi Sorimachi, Carsten T. Beuckmann, Michiyuki Suzuki, Takashi Ueno, Shunsuke Ozaki & Masahiro Yonaga. (2015) Discovery of (1 R ,2 S )-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)- N -(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist . Journal of Medicinal Chemistry 58:11, pages 4648-4664.
Crossref
Daisuke Minehira, Satoyuki Takahara, Isao Adachi & Naoki Toyooka. (2014) Laboratory and practical synthesis of Suvorexant, a selective dual orexin receptor antagonist. Tetrahedron Letters 55:42, pages 5778-5780.
Crossref
Artur Pałasz, Damien Lapray, Christelle Peyron, Ewa Rojczyk-Gołębiewska, Rafał Skowronek, Grzegorz Markowski, Beata Czajkowska, Marek Krzystanek & Ryszard Wiaderkiewicz. (2013) Dual orexin receptor antagonists – promising agents in the treatment of sleep disorders. The International Journal of Neuropsychopharmacology 17:01, pages 157-168.
Crossref
Richard B. Silverman & Mark W. Holladay. 2014. The Organic Chemistry of Drug Design and Drug Action. The Organic Chemistry of Drug Design and Drug Action 123 163 .
Derek J Leishman & Zoran Rankovic. 2015. Tactics in Contemporary Drug Design. Tactics in Contemporary Drug Design 225 259 .
Matthias Hoch, Justin L. Hay, Petra Hoever, Marieke L. de Kam, Erik T. te Beek, Joop M.A. van Gerven & Jasper Dingemanse. (2013) Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humans. European Neuropsychopharmacology 23:2, pages 107-117.
Crossref
Seema Gulyani, Rachel E. Salas & Charlene E. Gamaldo. (2012) Sleep Medicine Pharmacotherapeutics Overview. Chest 142:6, pages 1659-1668.
Crossref
Christopher J. Winrow, Anthony L. Gotter, Paul J. Coleman, Richard Hargreaves & John J. Renger. 2012. Drug Discovery for Psychiatric Disorders. Drug Discovery for Psychiatric Disorders 416 442 .
Anthony L. Gotter, Andrea L. Webber, Paul J. Coleman, John J. Renger & Christopher J. Winrow. (2012) International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology. Pharmacological Reviews 64:3, pages 389-420.
Crossref
Alexander Heifetz, G. Benjamin Morris, Philip C. Biggin, Oliver Barker, Tara Fryatt, Jonathan Bentley, David Hallett, Dominique Manikowski, Sandeep Pal, Rita Reifegerste, Mark Slack & Richard Law. (2012) Study of Human Orexin-1 and -2 G-Protein-Coupled Receptors with Novel and Published Antagonists by Modeling, Molecular Dynamics Simulations, and Site-Directed Mutagenesis. Biochemistry 51:15, pages 3178-3197.
Crossref
Paolo Bettica, Lisa Squassante, John A Groeger, Brian Gennery, Raphaelle Winsky-Sommerer & Derk-Jan Dijk. (2012) Differential Effects of a Dual Orexin Receptor Antagonist (SB-649868) and Zolpidem on Sleep Initiation and Consolidation, SWS, REM Sleep, and EEG Power Spectra in a Model of Situational Insomnia. Neuropsychopharmacology 37:5, pages 1224-1233.
Crossref
Anthony L. Gotter, Anthony J. Roecker, Richard Hargreaves, Paul J. Coleman, Christopher J. Winrow & John J. Renger. 2012. Orexin/Hypocretin System. Orexin/Hypocretin System 163 188 .
Urs Albrecht. (2011) Circadian rhythms and sleep?the metabolic connection. Pfl?gers Archiv - European Journal of Physiology 463:1, pages 23-30.
Crossref
Birgitta Norstedt Wikner & Bengt Källén. (2011) Are Hypnotic Benzodiazepine Receptor Agonists Teratogenic in Humans?. Journal of Clinical Psychopharmacology 31:3, pages 356-359.
Crossref
Carl A. BaxterEd CleatorKarel M. J. Brands, John S. EdwardsRobert A. Reamer, Faye J. SheenGavin W. StewartNeil A. Strotman & Debra J. Wallace. (2011) The First Large-Scale Synthesis of MK-4305: A Dual Orexin Receptor Antagonist for the Treatment of Sleep Disorder. Organic Process Research & Development 15:2, pages 367-375.
Crossref
Richard J Ward, John D Pediani & Graeme Milligan. (2011) Ligand-induced internalization of the orexin OX1 and cannabinoid CB1 receptors assessed via N-terminal SNAP and CLIP-tagging. British Journal of Pharmacology 162:6, pages 1439-1452.
Crossref
Michel A Steiner, Hugues Lecourt, Daniel S Strasser, Catherine Brisbare-Roch & François Jenck. (2010) Differential Effects of the Dual Orexin Receptor Antagonist Almorexant and the GABAA-α1 Receptor Modulator Zolpidem, Alone or Combined with Ethanol, on Motor Performance in the Rat. Neuropsychopharmacology 36:4, pages 848-856.
Crossref
Massimo Gianotti, Maurizio Botta, Stephen BroughRenzo Carletti, Emiliano Castiglioni, Corrado Corti, Michele Dal-Cin, Sonia Delle Fratte, Denana Korajac, Marija Lovric, Giancarlo Merlo, Milan Mesic, Francesca Pavone, Laura Piccoli, Slavko Rast, Maja Roscic, Anna Sava, Mario Smehil, Luigi Stasi, Andrea Togninelli & Mark J. Wigglesworth. (2010) Novel Spirotetracyclic Zwitterionic Dual H 1 /5-HT 2A Receptor Antagonists for the Treatment of Sleep Disorders . Journal of Medicinal Chemistry 53:21, pages 7778-7795.
Crossref
Massimo Gianotti, Corrado Corti, Sonia Delle Fratte, Romano Di Fabio, Colin P. Leslie, Francesca Pavone, Laura Piccoli, Luigi Stasi & Mark J. Wigglesworth. (2010) Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders. Bioorganic & Medicinal Chemistry Letters 20:17, pages 5069-5073.
Crossref
Christopher D. Cox, Michael J. Breslin, David B. Whitman, John D. Schreier, Georgia B. McGaughey, Michael J. Bogusky, Anthony J. Roecker, Swati P. Mercer, Rodney A. Bednar, Wei Lemaire, Joseph G. Bruno, Duane R. Reiss, C. Meacham Harrell, Kathy L. Murphy, Susan L. Garson, Scott M. Doran, Thomayant Prueksaritanont, Wayne B. Anderson, Cuyue Tang, Shane Roller, Tamara D. Cabalu, Donghui Cui, George D. Hartman, Steven D. Young, Ken S. Koblan, Christopher J. Winrow, John J. Renger & Paul J. Coleman. (2010) Discovery of the Dual Orexin Receptor Antagonist [(7 R )-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2 H -1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the Treatment of Insomnia . Journal of Medicinal Chemistry 53:14, pages 5320-5332.
Crossref
Shannon S. Sullivan. (2010) Insomnia Pharmacology. Medical Clinics of North America 94:3, pages 563-580.
Crossref
John R. Atack. 2010. GABA and Sleep. GABA and Sleep 25 72 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.